Two patent-related disputes involving Amgen products were resolved in the first days of 2019, temporarily halting sales of a competitor for one of its top products but clearing the way for another rival drug to hit the markets. The Supreme Court announced its decision Jan. 7 not to hear an appeal by the Thousand Oaks-based…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
